Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Preclinical Investigation of 212Pb-DOTAMTATE for Peptide Receptor Radionuclide Therapy in a Neuroendocrine Tumor Model.

Stallons TAR, Saidi A, Tworowska I, Delpassand ES, Torgue JJ.

Mol Cancer Ther. 2019 May;18(5):1012-1021. doi: 10.1158/1535-7163.MCT-18-1103. Epub 2019 Mar 29.

PMID:
30926632
2.

Cardiac Toxicity in a Patient Receiving Peptide Receptor Radionuclide Therapy.

Hendifar AE, Delpassand ES, Kittleson MM, Tuli R.

Pancreas. 2018 Sep;47(8):e55-e56. doi: 10.1097/MPA.0000000000001101. No abstract available.

PMID:
30113434
3.

Safety and Effectiveness of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy After Regional Hepatic Embolization in Patients With Somatostatin-Expressing Neuroendocrine Tumors.

Hamiditabar M, Ali M, Bolek L, Vahdati G, Tworowska I, Delpassand ES.

Clin Nucl Med. 2017 Nov;42(11):822-828. doi: 10.1097/RLU.0000000000001818.

PMID:
28832377
4.

Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors: Six Years' Assessment.

Hamiditabar M, Ali M, Roys J, Wolin EM, O╩╝Dorisio TM, Ranganathan D, Tworowska I, Strosberg JR, Delpassand ES.

Clin Nucl Med. 2017 Jun;42(6):436-443. doi: 10.1097/RLU.0000000000001629.

PMID:
28263217
5.

Assessment of vulnerable atherosclerotic and fibrotic plaques in coronary arteries using (68)Ga-DOTATATE PET/CT.

Mojtahedi A, Alavi A, Thamake S, Amerinia R, Ranganathan D, Tworowska I, Delpassand ES.

Am J Nucl Med Mol Imaging. 2014 Dec 15;5(1):65-71. eCollection 2015.

6.

The value of (68)Ga-DOTATATE PET/CT in diagnosis and management of neuroendocrine tumors compared to current FDA approved imaging modalities: a review of literature.

Mojtahedi A, Thamake S, Tworowska I, Ranganathan D, Delpassand ES.

Am J Nucl Med Mol Imaging. 2014 Aug 15;4(5):426-34. eCollection 2014. Review.

7.

Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience.

Delpassand ES, Samarghandi A, Zamanian S, Wolin EM, Hamiditabar M, Espenan GD, Erion JL, O'Dorisio TM, Kvols LK, Simon J, Wolfangel R, Camp A, Krenning EP, Mojtahedi A.

Pancreas. 2014 May;43(4):518-25. doi: 10.1097/MPA.0000000000000113.

PMID:
24632546
8.

Pictorial review of SPECT/CT imaging applications in clinical nuclear medicine.

Bhargava P, He G, Samarghandi A, Delpassand ES.

Am J Nucl Med Mol Imaging. 2012;2(2):221-31. Epub 2012 Mar 28.

9.

Long-Term Survival, Toxicity Profile, and role of F-18 FDG PET/CT scan in Patients with Progressive Neuroendocrine Tumors Following Peptide Receptor Radionuclide Therapy with High Activity In-111 Pentetreotide.

Delpassand ES, Samarghandi A, Mourtada JS, Zamanian S, Espenan GD, Sharif R, Mackenzie S, Kosari K, Barakat O, Naqvi S, Seng JE, Anthony L.

Theranostics. 2012;2(5):472-80. doi: 10.7150/thno.3739. Epub 2012 May 11.

10.

Peptide receptor radionuclide therapy in the United States.

Bhargava P, Delpassand ES.

J Nucl Med. 2012 May;53(5):839-40; author reply 840. doi: 10.2967/jnumed.112.104257. Epub 2012 Mar 15. No abstract available.

11.

Safety and efficacy of radionuclide therapy with high-activity In-111 pentetreotide in patients with progressive neuroendocrine tumors.

Delpassand ES, Sims-Mourtada J, Saso H, Azhdarinia A, Ashoori F, Torabi F, Espenan G, Moore WH, Woltering E, Anthony L.

Cancer Biother Radiopharm. 2008 Jun;23(3):292-300. doi: 10.1089/cbr.2007.0448.

PMID:
18593362
12.

Lymphatic drainage patterns on early versus delayed breast lymphoscintigraphy performed after injection of filtered Tc-99m sulfur colloid in breast cancer patients undergoing sentinel lymph node biopsy.

Babiera GV, Delpassand ES, Breslin TM, Ross MI, Ames FC, Singletary SE, Kuerer HM, Feig BW, Meric-Bernstam F, Hunt KK.

Clin Nucl Med. 2005 Jan;30(1):11-5.

PMID:
15604959
13.

Radiolabeled antibody therapy in non-Hodgkins lymphoma: radiation protection, isotope comparisons and quality of life issues.

Silverman DH, Delpassand ES, Torabi F, Goy A, McLaughlin P, Murray JL.

Cancer Treat Rev. 2004 Apr;30(2):165-72. Review.

PMID:
15023434
14.

Potential role for intraoperative gamma probe identification of normal parathyroid glands.

Pederson LC, Shapiro SE, Fritsche HA Jr, Delpassand ES, Gagel RF, Sherman SI, Vassilopoulou-Sellin R, Evans DB, Lee JE.

Am J Surg. 2003 Dec;186(6):711-7.

PMID:
14672784
15.

Imaging in cervical cancer.

Follen M, Levenback CF, Iyer RB, Grigsby PW, Boss EA, Delpassand ES, Fornage BD, Fishman EK.

Cancer. 2003 Nov 1;98(9 Suppl):2028-38. Review.

16.

A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases.

Pagliaro LC, Delpassand ES, Williams D, Millikan RE, Tu SM, Logothetis CJ.

Cancer. 2003 Jun 15;97(12):2988-94.

17.

Improving the yield of preoperative parathyroid localization: technetium Tc 99m-sestamibi imaging after thyroid suppression.

Royal RE, Delpassand ES, Shapiro SE, Fritsche HA Jr, Vassilopoulou-Sellin R, Sherman SI, Gagel RF, Evans DB, Lee JE.

Surgery. 2002 Dec;132(6):968-74; discussion 974-5.

PMID:
12490843
18.

Lymphatic mapping and sentinel node identification in patients with cervix cancer undergoing radical hysterectomy and pelvic lymphadenectomy.

Levenback C, Coleman RL, Burke TW, Lin WM, Erdman W, Deavers M, Delpassand ES.

J Clin Oncol. 2002 Feb 1;20(3):688-93.

PMID:
11821449
19.

Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial.

Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, Daliani D, Papandreou CN, Smith TL, Kim J, Podoloff DA, Logothetis CJ.

Lancet. 2001 Feb 3;357(9253):336-41. Erratum in: Lancet 2001 Apr 14;357(9263):1210.

PMID:
11210994
20.

Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer.

Breslin TM, Cohen L, Sahin A, Fleming JB, Kuerer HM, Newman LA, Delpassand ES, House R, Ames FC, Feig BW, Ross MI, Singletary SE, Buzdar AU, Hortobagyi GN, Hunt KK.

J Clin Oncol. 2000 Oct 15;18(20):3480-6.

PMID:
11032588
21.

Relative contributions of technetium Tc 99m sestamibi scintigraphy, intraoperative gamma probe detection, and the rapid parathyroid hormone assay to the surgical management of hyperparathyroidism.

Dackiw AP, Sussman JJ, Fritsche HA Jr, Delpassand ES, Stanford P, Hoff A, Gagel RF, Evans DB, Lee JE.

Arch Surg. 2000 May;135(5):550-5; discussion 555-7. Review.

PMID:
10807279
22.
23.

Role of indium-111 labelled platelet scintigraphy in the management of thrombocytopenic patients with malignant neoplasms.

Oriuchi N, Korkmaz M, Kim EE, Delpassand ES, Wong F, Wallace S, Podoloff DA.

Eur J Nucl Med. 1998 Mar;25(3):247-52.

PMID:
9580857
24.

Prognosis and treatment of brain metastases in thyroid carcinoma.

Chiu AC, Delpassand ES, Sherman SI.

J Clin Endocrinol Metab. 1997 Nov;82(11):3637-42.

PMID:
9360519
25.

Differentiation between benign and malignant breast lesions with MR imaging and scintimammography.

Delpassand ES, Jackson EF.

Radiology. 1997 Oct;205(1):283-4; author reply 285-6. No abstract available.

PMID:
9315002
26.

Phase II trial of hepatic arterial infusion of fluorouracil and recombinant human interferon alfa-2b for liver metastases of colorectal cancer refractory to systemic fluorouracil and leucovorin.

Patt YZ, Hoque A, Lozano R, Pozdur R, Chase J, Carrasco H, Chuang V, Delpassand ES, Ellis L, Curley S, Roh M, Jones DV Jr.

J Clin Oncol. 1997 Apr;15(4):1432-8.

PMID:
9193336
27.

Strontium-89 combined with doxorubicin in the treatment of patients with androgen-independent prostate cancer.

Tu SM, Delpassand ES, Jones D, Amato RJ, Ellerhorst J, Logothetis CJ.

Urol Oncol. 1996 Nov-Dec;2(6):191-7.

PMID:
21224168
28.

Synthesis, biodistribution, and estrogen receptor scintigraphy of indium-111-diethylenetriaminepentaacetic acid-tamoxifen analogue.

Delpassand ES, Yang DJ, Wallace S, Cherif A, Quadri SM, Price J, Joubert A, Inoue T, Podoloff DA.

J Pharm Sci. 1996 Jun;85(6):553-9.

PMID:
8773948
29.

Value of SPECT imaging of the thoracolumbar spine in cancer patients.

Delpassand ES, Garcia JR, Bhadkamkar V, Podoloff DA.

Clin Nucl Med. 1995 Dec;20(12):1047-51.

PMID:
8674287
30.

Rapid identification of common human pathogens by high-resolution proton magnetic resonance spectroscopy.

Delpassand ES, Chari MV, Stager CE, Morrisett JD, Ford JJ, Romazi M.

J Clin Microbiol. 1995 May;33(5):1258-62.

31.

Radiation-induced heart disease: imaging features.

Loyer EM, Delpassand ES.

Semin Roentgenol. 1993 Oct;28(4):321-32. Review. No abstract available.

PMID:
8272880
32.

Nuclear hepatobiliary imaging.

Kim EE, Moon TY, Delpassand ES, Podoloff DA, Haynie TP.

Radiol Clin North Am. 1993 Jul;31(4):923-33. Review.

PMID:
8337375
33.

Evaluation of soft tissue injury by Tc-99m bone agent scintigraphy.

Delpassand ES, Dhekne RD, Barron BJ, Moore WH.

Clin Nucl Med. 1991 May;16(5):309-14.

PMID:
1647284
34.

Bone scintigraphy in calcific discitis of childhood.

Delpassand ES, Barron BJ, Gundzik JM.

J Nucl Med. 1990 Feb;31(2):234-6.

PMID:
2313363
35.

Cavernous sinus syndrome as the presentation of malignant lymphoma: case report and review of the literature.

Delpassand ES, Kirkpatrick JB.

Neurosurgery. 1988 Oct;23(4):501-4. Review.

PMID:
3059213

Supplemental Content

Loading ...
Support Center